Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo
- 1 January 2001
- journal article
- Published by Elsevier in Journal of Hepatology
- Vol. 34 (1) , 114-122
- https://doi.org/10.1016/s0168-8278(00)00074-x
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- Lamivudine as Initial Treatment for Chronic Hepatitis B in the United StatesNew England Journal of Medicine, 1999
- Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapyHepatology, 1999
- A One-Year Trial of Lamivudine for Chronic Hepatitis BNew England Journal of Medicine, 1998
- Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapyJournal of Hepatology, 1998
- Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study.Gastroenterology, 1997
- The Treatment of Chronic Viral HepatitisNew England Journal of Medicine, 1997
- Viral dynamics in hepatitis B virus infection.Proceedings of the National Academy of Sciences, 1996
- Hepatitis B reactivation after lamivudineThe Lancet, 1995
- Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidineAntimicrobial Agents and Chemotherapy, 1995
- Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues.Proceedings of the National Academy of Sciences, 1991